ArticleLeukemia & lymphoma2020
Low absolute CD4
Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06762470 (Prognostic Value of Pretreatment Peripheral Circulating Lymphocyte CD4/CD8 Ratio in Patients with Non-metastatic Nasopharyngeal Carcinoma), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Value of Pretreatment Peripheral Circulating Lymphocyte CD4/CD8 Ratio in Patients with Non-metastatic Nasopharyngeal Carcinoma: a Multi-center Prospective Observational Study
Who cites it
19 citing papers in PubMed.
- SSTNSignal transduction and targeted therapy · 2026Article
- Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.Haematologica · 2026Article
- Altered dynamics of T cell subsets in peripheral blood impacts disease progression in newly diagnosed multiple myeloma.Biochemistry and biophysics reports · 2025Article
- Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Prognostic value of lymphocyte subsets in diffuse large B cell lymphoma.Frontiers in oncology · 2025Article
- Different evasion strategies in multiple myeloma.Frontiers in immunology · 2024Review
- The effects of aging, sex, and tumor burden on the peripheral blood immune cell profile and absolute counts.Journal of Cancer · 2024Article
- Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.Frontiers in immunology · 2024Observational
- Baseline absolute lymphocyte count as a prognostic indicator in advanced or metastatic breast cancer: a systematic review and meta-analysis.American journal of translational research · 2024Article
- Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.Hematology reports · 2023Review
- Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma.Journal of neuro-oncology · 2022Article
- Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.Journal of hematology & oncology · 2022Review
- The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients.Contrast media & molecular imaging · 2022Article
- Reference ranges of T lymphocyte subsets by single-platform among healthy population in southwest China.BMC immunology · 2021Article
- Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.Nature communications · 2021Article
- Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.Cancers · 2021Review
- The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.BioMed research international · 2021Article
- Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield.Leukemia & lymphoma · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The T lymphocyte system plays an active role in tumor immunosurveillance in multiple myeloma (MM), and abnormal T lymphocyte populations are often observed in patients with MM. In the current study, we evaluated the prognostic impact of abnormal T lymphocyte subset distributions in patients with newly diagnosed MM (NDMM). Between December 2012 to October 2016, 110 NDMM patients were included in this study. Multiparameter flow cytometry was applied to quantitatively analysis the peripheral blood T lymphocyte subsets, including CD4
Indexed as
Identifiers
32324088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.